Key Highlights

  • USD 100 million upfront and up to USD 1.17 billion in milestones: the price Genentech, a Roche Group member, agreed on October 5, 2026 to license AL050, the Parkinson's program of Alector (NASDAQ:ALEC), plus tiered royalties on net sales.
  • Into 2029: the cash runway Alector now expects, with preliminary cash of USD 138.7 million at September 30, 2026 and USD 223.7 million pro forma after the Genentech and Spur payments, according to the company's 8-K.
  • USD 15 million: what Alector (NASDAQ:ALEC) must pay Spur after receiving the upfront, plus a percentage in the teens of milestone and similar partnering income tied to the Spur patents, per the same 8-K filing.
  • Near USD 2.8: where Alector (NASDAQ:ALEC) shares traded premarket on October 5, 2026, approaching the 52-week high of USD 3.40, according to published market data, which leaves less cushion if milestones slip or timelines stretch.

What Genentech Is Paying For

On October 5, 2026 at 7:00 a.m. ET, Alector announced an exclusive global license giving Genentech worldwide rights to AL050, a brain-penetrant enzyme replacement therapy for Parkinson's disease built on the Alector Brain Carrier platform, designed to move drugs across the blood-brain barrier. Genentech takes over development, regulatory work, Manufacturing and sales. Alector receives USD 100 million upfront, up to USD 1.17 billion in milestones and tiered royalties. The USD 1.27 billion headline is the sum of the first two figures, simple arithmetic, and only the upfront is certain.

Cash, Spur and the Runway

Alector will pay Spur USD 15 million from the upfront, plus a percentage in the teens of milestone income. Preliminary cash, cash equivalents and marketable securities were about USD 138.7 million at September 30, 2026, or about USD 223.7 million pro forma for the initial payments, which management says funds operations into 2029. Earlier filings pointed to a runway through 2027. The extra time supports its Alzheimer's antibody and its Tau and alpha-synuclein programs, which remain early stage.

What Could Go Wrong

AL050 is preclinical, so milestones depend on years of development and regulatory success that may not occur. Published coverage describes the deal as a reset after a series of clinical-stage failures. Shares traded near USD 2.8 premarket, close to the 52-week high of USD 3.40, so much of the good news may already be priced in. Spur takes a share of milestones, which means headline value overstates what Alector keeps if every payment arrives.

Where Things Stand

Partly. Alector (NASDAQ:ALEC) has repaired its balance sheet, but it has not validated a product, so the market is arguably paying for the upfront cash rather than the milestones. The USD 100 million is certain, the runway reaches 2029 and the partner is Roche, yet AL050 is preclinical and most of the USD 1.17 billion is contingent. Next catalysts are the third quarter results, Alzheimer's antibody progress and any Genentech milestone triggers, none of which has a confirmed date. The shares moved on certainty of cash, and the milestone stream will take years to test.